⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL888716 | 1.00 | — | — | |
| SCHEMBL17999775 | 1.00 | — | — | |
| SCHEMBL2706246 | 0.91 | — | — | |
| SCHEMBL15828959 | 0.91 | — | — | |
| SCHEMBL888603 | 0.91 | — | — | |
| SCHEMBL888732 | 0.91 | — | — | |
| SCHEMBL888617 | 0.86 | — | — | |
| SCHEMBL25760127 | 0.83 | — | — | |
| SCHEMBL888615 | 0.81 | — | — | |
| SCHEMBL2707369 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037340-B2 | Pentacyclic derivatives as Zika virus inhibitors | GILEAD SCIENCES, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037340-B2 | Pentacyclic derivatives as Zika virus inhibitors | GILEAD SCIENCES, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20220411434-A1 | PENTACYCLIC DERIVATIVES AS ZIKA VIRUS INHIBITORS | GILEAD SCIENCES, INC. | 2022-12-29 | — | — | US | disclosed |
| US-20220402931-A1 | TETRACYCLIC COMPOUNDS AND METHODS FOR THE TREATMENT OF ZIKA VIRUS INFECTION | GILEAD SCIENCES, INC. | 2022-12-22 | — | — | US | disclosed |
| WO-2022246072-A1 | TETRACYCLIC COMPOUNDS FOR THE TREATMENT OF ZIKA VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2022-11-24 | — | — | WO | disclosed |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2020-04-23 | — | — | US | disclosed |
| US-10344019-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2019-07-09 | — | — | US | disclosed |
| US-9981955-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981955-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180118680-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-8293929-B2 | Processes and intermediates | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-23 | — | — | US | disclosed |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8273341-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110071298-A1 | Processes and Intermediates | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-24 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
| US-7834200-B2 | Processes and intermediates | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090048429-A1 | Processes and intermediates | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-19 | — | — | US | disclosed |
| US-7381827-B2 | 5-Ethoxy-4-(1-(benzyloxycarbonyl)-2-pyrrolidinylcarbonylamino)-5H-furan-2-one; purification by chromatography, selectively crystallization, or dynamic crystallization; useful for preparing caspase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-06-03 | — | — | US | disclosed |